comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 04:10:07 - browse：43424

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The debate over Covid

hotspot

WSS

AI can’t replace a physician’s gut feeling

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Blinken talks high

One Duchenne patient's bittersweet hope for new treatment

Cosmetics set for new safety regulation. Why the industry is on board

Startup Neumora takes a novel depression drug to Phase 3

knowledge

comprehensive

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

WHO calls for emergency meeting on new China virus, as cases spread

BioMarin wins approval for gene therapy to treat hemophilia A

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Moonlake's readout produced a cash windfall. Risks remain

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Hollywood unions extend contract negotiations for actors

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

DIEP, the 'gold standard' of breast reconstruction, is under threat

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

explore

Medicare to cover more brain scans for Alzheimer’s patients

The debate over Covid

Grail's uphill battle for Medicare to cover its cancer screening test

How are insurers handling Leqembi and related scans?

Biden tests positive for Covid

Companies helping big Covid

hotspot

hotspot

focus

knowledge